Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,348 recruiting studies in this area right now.
By phase
- Not applicable9,612
- Phase 24,442
- Phase 12,685
- Phase 1/Phase 21,654
- Phase 31,400
- Phase 2/Phase 3287
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer648
- Cancer636
- Colorectal Cancer476
- Lung Cancer421
- Ovarian Cancer341
- Multiple Myeloma329
- Pancreatic Cancer288
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma259
- Solid Tumor245
- Advanced Solid Tumor231
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors208
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,401
- Texas636
- Arizona508
- Florida439
- Alabama430
- New York406
- Massachusetts340
- Maryland330
- New Jersey275
- Pennsylvania236
Recruiting studies20,348 total
- NCT05779423RecruitingPhase 2
Freezing tumor plus two immunotherapies for advanced melanoma
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Boston, MassachusettsAges 18 years+ - NCT05791409RecruitingPhase 1/Phase 2
Venetoclax plus epcoritamab for relapsed or refractory CLL
This early-phase study tests whether combining venetoclax (a tablet) with epcoritamab (a targeted antibody) can control CLL/SLL that has come back or did not respond. It may help by boosting the immune system’s ability to attack the cancer while keeping the treatment schedule in cycles.
MelbourneAges 18 years+ - NCT05792150Recruiting
Registry for young women with certain early breast cancer treatments
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Baden-Baden, Baden-WurttembergAges 18–60 - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Duarte, CaliforniaAges 18–100 - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05803941RecruitingPhase 4
Study long-term safety of a prostate cancer drug
This trial checks the long-term safety (how it affects you over time) of lutetium-177 vipivotide tetraxetan in people with prostate cancer. You may be eligible if you already received the related drug in a prior Novartis prostate cancer study and can complete the required follow-up tests.
Scottsdale, ArizonaAges 18–100 - NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Duarte, CaliforniaAges 18 years+ - NCT05804370RecruitingPhase 3
Gleolan to help surgeons find ovarian cancer during surgery
This Phase 3 study tests whether Gleolan (a medicine given before surgery) helps doctors better see ovarian, fallopian tube, or peritoneal cancer during an operation. It may help improve how well surgeons can remove visible tumor tissue during planned surgery.
Phoenix, ArizonaAges 18 years+ - NCT05781555Recruiting
DaRT radiation device study for treating tumors
This study tests a radiation-emitting device (called DaRT) for treating cancer tumors. It may help shrink or control malignant tumors and researchers will check safety and response to the treatment.
JerusalemAges 18 years+ - NCT05798819RecruitingPhase 3
PD-L1 cervical cancer trial with chemotherapy and possible bevacizumab
This Phase 3 study tests GLS-010 added to standard platinum chemotherapy, with or without bevacizumab, as a first treatment for cervical cancer that has persisted, come back, or spread. If you have PD-L1–positive tumors, the goal is to improve how long people can control the cancer compared with standard chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Duarte, CaliforniaAges 18–130 - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT05800977RecruitingPhase 1/Phase 2
Study of a CAR-T cell treatment for lymphoma that returned
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
BeijingAges 18 years+ - NCT05387863Recruiting
Decision aid for people with small kidney tumors
This trial tests a decision aid—a simple guide—to help kidney cancer patients understand options and make choices with their urology team. It may help you feel more informed and confident before or after your kidney procedure.
New York, New YorkAges 18 years+ - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05777603RecruitingPhase 1
Aerosol antibiotics plus pembrolizumab for advanced lung cancer
This trial studies whether inhaled (aerosol) antibiotics combined with pembrolizumab can help people with advanced non-small cell lung cancer that has grown despite standard first treatment. It aims to improve cancer control by testing this new combination in Phase 1 safety and early effectiveness.
Bethesda, MarylandAges 18–120 - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05755113RecruitingPhase 2
Testing a drug injected into tumors for soft tissue sarcoma
This trial tests whether a medicine injected directly into a tumor can shrink or control advanced soft tissue sarcoma. It mainly looks for people whose tumors can be safely injected with a hand exam or ultrasound.
New York, New YorkAges 18 years+ - NCT05759728RecruitingPhase 1/Phase 2
LGR5-targeted CAR-T for metastatic colorectal cancer
This early-phase study tests an autologous CAR-T cell treatment that is designed to recognize LGR5 on colorectal cancer cells. It aims to shrink metastatic colorectal cancer that has already been treated with up to two prior standard chemotherapy regimens.
Adelaide, South AustraliaAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,348 recruiting oncology studies from the U.S. registry right now, out of 31,535 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.